Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Clinical Investigation to Compare Orlistat 60 mg and a Customized Polyglucosamine, Two Treatment Methods for the Management of Overweight and Obesity
This trial compares two treatment methods: 1. Orlistat 60 mg to be taken three times daily one capsule; indicated for weight loss in overweight adults. Important is also that it is taken along with a reduced-calorie and low-fat diet. 2. Polyglucosamine tablets to be taken two times daily two tablets, taken with the two main meals with the highest fat content, indicated for weight maintenance and weight loss.
Age
21 - 70 years
Sex
ALL
Healthy Volunteers
Yes
Diabetological Center
Dreieich, Hesse, Germany
MAP Center
Rende, Cosenza, Italy
Start Date
November 1, 2009
Primary Completion Date
June 1, 2010
Completion Date
August 1, 2013
Last Updated
August 20, 2015
64
ACTUAL participants
orlistat 60 mg
DRUG
polyglucosamine
DEVICE
Lead Sponsor
Certmedica International GmbH
NCT01143454
NCT07472881
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions